ProCE Banner Activity

REACH-2: Phase III Second-line Ramucirumab vs Placebo in Advanced Hepatocellular Carcinoma With Elevated Baseline AFP Following First-line Sorafenib

Slideset Download
Conference Coverage
Ramucirumab showed a significant survival benefit in patients with advanced HCC and a baseline AFP ≥ 400 mg/mL following previous sorafenib treatment.

Released: June 08, 2018

Expiration: June 07, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen